Medullary Thyroid Carcinoma Management and Prognosis
Summary
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy arising from parafollicular C-cells, accounting for approximately 1–2 percent of all thyroid cancers. Its clinical management hinges on accurate genetic, biochemical and imaging assessments to guide surgery, systemic therapy and long-term surveillance. Genetic testing for germline and somatic alterations in the RET proto-oncogene underpins risk stratification and timely prophylactic interventions in hereditary cases. Biochemical markers such as calcitonin and carcinoembryonic antigen (CEA) serve both diagnostic and prognostic roles, with doubling times informing the pace of disease progression. Ultrasonography remains the first-line imaging modality for local staging, whereas advanced nuclear imaging techniques—including PET/CT with novel radioligands—enhance detection of recurrent or metastatic foci. Surgical approach is tailored by tumour size, nodal involvement and extrathyroidal extension, while selective RET kinase inhibitors have transformed outcomes in patients harbouring actionable mutations. Despite these advances, prognosis varies widely according to genetic profile, structural invasion and response to targeted therapies, emphasising the need for multidisciplinary care and ongoing research.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Medullary Thyroid Carcinoma Management and Prognosis publication trend
The graph below shows the total number of articles in medullary thyroid carcinoma management and prognosis across all publications each year (not limited to Nature Index journals).
Technical terms
RET proto-oncogene: A gene encoding a receptor tyrosine kinase that, when mutated, drives hereditary and sporadic forms of MTC.
Kinase inhibitor: A class of targeted agents that block aberrant kinase signalling, pivotal in the treatment of RET-mutant MTC.
Calcitonin: A hormone produced by C-cells; elevated serum levels serve as a sensitive biomarker for MTC.
Positron emission tomography (PET/CT): An advanced imaging modality combining metabolic tracer uptake with anatomical detail, essential for detecting recurrent or metastatic MTC.
Carcinoembryonic antigen (CEA): A glycoprotein tumour marker often elevated alongside calcitonin, used for prognosis and surveillance.
References
- Medullary Thyroid Cancer: Updates and Challenges. Endocrine Reviews (2023).
- Prevalence and significance of indeterminate calcitonin values in patients with thyroid nodules: A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders (2023).
- Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine. Seminars in Nuclear Medicine (2023).
- Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. British Journal of Cancer (2009).
- Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. Genes (2019).
- Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single‐Institution Study in Japan. World Journal of Surgery (2018).
- Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?. Annals of Surgical Oncology (2018).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.